{"id":"NCT01685242","sponsor":"Aciex Therapeutics, Inc.","briefTitle":"A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle","officialTitle":"A Single-Center, Double-Masked, Randomization, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of AC-170 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09","primaryCompletion":"2012-11","completion":"2012-11","firstPosted":"2012-09-14","resultsPosted":"2017-10-10","lastUpdate":"2017-10-10"},"enrollment":100,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Allergic Conjunctivitis"],"interventions":[{"type":"DRUG","name":"AC-170 0.24%","otherNames":[]},{"type":"DRUG","name":"AC-170 0%","otherNames":[]}],"arms":[{"label":"AC-170 0.24%","type":"EXPERIMENTAL"},{"label":"AC-170 0%","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.","primaryOutcome":{"measure":"Ocular Itching at Duration of Action (8 Hours + 30 Minutes Post-dose)","timeFrame":"3, 5, 7 minutes post-CAC","effectByArm":[{"arm":"AC-170 0.24%","deltaMin":1.76,"sd":0.94},{"arm":"AC-170 0%","deltaMin":2.69,"sd":0.663}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["Visual Acuity Reduced","Eye Pain","Punctate Keratitis","Lower Respiratory Tract Infection","Sinusitis"]}}